Aytu BioPharma, Inc. (AYTU)
AYTU Stock Price Chart
Explore Aytu BioPharma, Inc. interactive price chart. Choose custom timeframes to analyze AYTU price movements and trends.
AYTU Company Profile
Discover essential business fundamentals and corporate details for Aytu BioPharma, Inc. (AYTU) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Sept 2008
Employees
102.00
Website
https://aytubio.comCEO
Joshua R. Disbrow
Description
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
AYTU Financial Timeline
Browse a chronological timeline of Aytu BioPharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 10 Feb 2026
Upcoming earnings on 25 Sept 2025
EPS estimate is -$0.02.
Earnings released on 26 Jun 2025
Earnings released on 14 May 2025
EPS came in at $0.20 surpassing the estimated -$0.17 by +217.65%, while revenue for the quarter reached $18.45M , missing expectations by -2.02%.
Earnings released on 12 Feb 2025
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $16.22M , missing expectations by -7.77%.
Earnings released on 13 Nov 2024
EPS came in at -$0.20 surpassing the estimated -$0.34 by +41.18%, while revenue for the quarter reached $16.57M , beating expectations by +20.36%.
Earnings released on 26 Sept 2024
EPS came in at -$0.82 falling short of the estimated -$0.45 by -82.22%, while revenue for the quarter reached $17.98M , missing expectations by -1.77%.
Earnings released on 15 May 2024
EPS came in at -$0.52 surpassing the estimated -$0.64 by +18.75%, while revenue for the quarter reached $17.99M , missing expectations by -1.68%.
Earnings released on 14 Feb 2024
EPS came in at -$0.04 surpassing the estimated -$0.25 by +84.00%, while revenue for the quarter reached $22.93M , beating expectations by +5.49%.
Earnings released on 14 Nov 2023
EPS came in at -$1.48 falling short of the estimated -$0.04 by -3.60K%, while revenue for the quarter reached $22.10M , missing expectations by -20.31%.
Earnings released on 27 Sept 2023
EPS came in at $0.16 surpassing the estimated -$0.95 by +116.84%, while revenue for the quarter reached $30.73M , beating expectations by +10.99%.
Earnings released on 11 May 2023
EPS came in at -$1.93 falling short of the estimated -$0.63 by -206.35%, while revenue for the quarter reached $22.73M , missing expectations by -12.90%.
Earnings released on 21 Feb 2023
EPS came in at -$1.31 falling short of the estimated $0.20 by -755.00%, while revenue for the quarter reached $26.28M , missing expectations by -10.92%.
Stock split effective on 6 Jan 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2022
EPS came in at -$1.20 surpassing the estimated -$3.60 by +66.67%, while revenue for the quarter reached $27.66M , beating expectations by +13.81%.
Earnings released on 27 Sept 2022
EPS came in at -$5.00 falling short of the estimated -$4.80 by -4.17%, while revenue for the quarter reached $27.45M , beating expectations by +6.80%.
Earnings released on 16 May 2022
EPS came in at -$5.40 surpassing the estimated -$8.20 by +34.15%, while revenue for the quarter reached $24.20M , missing expectations by 0.00%.
Earnings released on 14 Feb 2022
EPS came in at -$8.80 falling short of the estimated -$7.09 by -24.14%, while revenue for the quarter reached $23.13M , beating expectations by +0.11%.
Earnings released on 15 Nov 2021
EPS came in at -$6.60 falling short of the estimated -$2.97 by -122.45%, while revenue for the quarter reached $21.90M , beating expectations by +19.99%.
Earnings released on 27 Sept 2021
EPS came in at -$13.40 falling short of the estimated -$3.20 by -318.75%, while revenue for the quarter reached $23.48M .
Earnings released on 17 May 2021
EPS came in at -$3.40 surpassing the estimated -$7.20 by +52.78%, while revenue for the quarter reached $13.48M , missing expectations by -8.16%.
Earnings released on 11 Feb 2021
EPS came in at -$9.40 surpassing the estimated -$10.00 by +6.00%, while revenue for the quarter reached $15.15M , beating expectations by +23.65%.
Stock split effective on 9 Dec 2020
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Nov 2020
EPS came in at -$8.00 surpassing the estimated -$12.00 by +33.33%, while revenue for the quarter reached $13.52M , missing expectations by -16.67%.
Earnings released on 6 Oct 2020
EPS came in at -$4.00 surpassing the estimated -$7.00 by +42.86%, while revenue for the quarter reached $14.86M , missing expectations by -18.58%.
AYTU Stock Performance
Access detailed AYTU performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.